Carvykti (ciltacabtagene autoleucel), new gene therapy to treat adult patients with multiple myeloma
EMA has recommended a conditional marketing authorisation in the European Union…
Abecma (idecabtagene vicleucel), First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma
The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel),…
Blenrep (belantamab mafodotin), new option for the treatment of relapsed and refractory multiple myeloma
EMA’s human medicines committee (CHMP) has recommended granting a conditional…
Sarclisa (isatuximab-irfc), new Therapy for Patients with Previously Treated Multiple Myeloma
The FDA has approved Sarclisa (isatuximab-irfc), in combination with…
FDA approves Xpovio (selinexor), new treatment for refractory multiple myeloma
The FDA has granted accelerated approval to Xpovio (selinexor) tablets in…